GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Marinomed Biotech MARI.VI · EUR

Health Care · Wiener Börse · 🇦🇹 Austria

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

€7.7m

FY2016FY2025

Net income

€15.3m

FY2016FY2025

Free cash flow

−€1.1m

FY2016FY2025

Shareholders' equity

−€9.8m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue€7.7m€4.7m€9.2m€11.3m€11.6m€8.1m€6.1m€4.7m€4.8m€2.6m
Gross profit€2.0m−€4.3m€1.1m€2.1m€1.4m−€641,700−€512,300−€165,446€651,422€176,155
Research and development€23,310€255,000€1.2m€6.9m€7.5m€5.9m€4.8m€2.9m€2.2m€2.7m
Operating income€18.7m−€7.0m−€5.1m−€5.8m−€4.1m−€7.0m−€6.2m−€5.1m−€1.6m−€1.5m
Net income€15.3m−€15.4m−€6.8m−€6.4m−€5.9m−€6.0m−€7.2m−€12.1m−€2.4m−€2.0m
Diluted earnings per share8.29-10.01-4.46-4.25-3.98-4.08-4.91-7.79-1.53-1.07

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets€6.0m€8.2m€14.6m€22.3m€21.3m€23.5m€19.5m€5.3m€9.3m€4.9m
Cash and short-term investments€1.0m€1.7m€2.6m€8.2m€5.8m€9.2m€12.0m€1.7m€6.0m€2.0m
Total liabilities€12.8m€34.1m€24.7m€26.4m€21.1m€18.1m€8.6m€21.5m€14.4m€7.6m
Debt€11.6m€29.5m€21.8m€22.6m€15.8m€12.8m€4.6m€10.6m€10.8m€5.9m
Shareholders' equity−€9.8m−€26.2m−€10.1m−€4.2m€191,400€5.4m€10.9m−€16.3m−€5.0m−€2.6m
Shares outstanding2m2m2m2m1m1m1m2m2m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−€1.1m−€2.4m−€4.5m−€5.2m−€4.9m−€6.9m−€7.6m−€4.3m−€2.2m−€2.5m
Capital spending——−€128,500−€227,600−€918,800−€4.0m−€2.3m−€229,083−€153,921−€112,526
Free cash flow−€1.1m−€2.4m−€4.7m−€5.4m−€5.8m−€10.8m−€10.0m−€4.5m−€2.3m−€2.6m

Latest quarters

By quarter end

Jun 2025Mar 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023
Revenue€7.2m€6.5m€4.7m€1.7m€737,500€2.0m€1.9m€1.9m
Gross profit€5.9m—€980,000€688,700−€1.5m−€1.2m€136,500€337,100
Operating income€21.0m€22.2m−€7.6m−€1.3m−€1.9m−€729,300−€1.5m−€1.5m
Net income€20.7m€22.1m−€15.4m−€8.7m−€2.1m−€1.2m−€2.1m−€1.5m
Diluted earnings per share11.6511.98-8.67-5.65-1.38-0.78-1.37-0.95
Cash from operations——————−€1.0m−€1.0m
Capital spending——————−€1.0m—
Free cash flow——————−€2.0m—
Total assets€7.6m—€8.2m€11.3m€12.1m€14.6m€15.2m€17.8m
Cash and short-term investments€1.5m—€1.7m€911,500€1.9m€2.6m€2.8m€5.4m
Debt€10.7m—€28.2m€29.1m€21.7m€7.0m€2.0m€21.6m
Shareholders' equity−€5.4m—−€26.2m−€20.5m−€11.8m−€10.1m−€9.1m−€7.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-11.9%-1.1%13.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin-18.2%3.1%3.4%3.9%
Operating margin93.8%2.4%-19.6%-35.6%
Net margin-0.9%-40.4%-47.9%-68.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings2.3-1.5-3.9-7.9-13.2-17.4-12.2
Price to sales4.64.92.94.56.712.914.3

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.